2023 World Conference on Lung Cancer (Posters)-EP06.03. Clinical Impact of Next-Generation Sequencing in KRAS-Mutated Non-Small Cell Lung Cancer Patients: a Single-Center Experience

EP06.03. Clinical Impact of Next-Generation Sequencing in KRAS-Mutated Non-Small Cell Lung Cancer Patients: a Single-Center Experience - PDF(Abstract)

Back to course

Pdf Summary

Next-generation sequencing (NGS) has become important in detecting driver mutations in non-small cell lung cancer (NSCLC) patients and informing treatment decisions. However, the clinical utility of NGS in NSCLC patients with KRAS mutations is not well understood. This study conducted a retrospective chart review of NSCLC patients receiving systemic therapy in a Greek hospital to evaluate the clinical impact of NGS in KRAS-mutated NSCLC patients.<br /><br />The study included 23 NSCLC patients, with a median age of 62 years. The majority of patients were smokers (90.5%) and had de novo metastatic disease at lung cancer diagnosis (69.6%). Most patients had adenocarcinoma (95.7%) as the histologic type, and the remaining patient had adenosquamous carcinoma. The detected KRAS mutations included G12C (52.2%), G12V (26.1%), G12D (13.0%), G12S (4.3%), and G13C (4.3%). Co-mutations in genes other than KRAS, such as MET and TP53, were detected in 16 patients (69.6%) with potential prognostic or predictive significance.<br /><br />After a median follow-up of 14.6 months, the median progression-free survival was 13.6 months, and the median overall survival was not reached. The use of NGS allowed for the detection of additional genetic alterations with potential clinical significance in the majority of KRAS-mutated patients.<br /><br />In conclusion, this study demonstrates the clinical impact of NGS in KRAS-mutated NSCLC patients. The use of NGS enabled the detection of additional genetic alterations that may have prognostic or predictive significance. These findings contribute to the growing body of evidence supporting the use of NGS in NSCLC patients to inform treatment decisions.

Asset Subtitle

Emmanouil Panagiotou

Meta Tag

Speaker Emmanouil Panagiotou

Topic Pathology & Biomarkers: Genetic Biomarkers

Keywords

next-generation sequencing

NGS

driver mutations

non-small cell lung cancer

NSCLC

treatment decisions

KRAS mutations

clinical utility

retrospective chart review

systemic therapy